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A B S T R A C T
Background
Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conserving surgery. It
may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen
if the shorter treatment is as effective and safe as conventional radiation therapy. This is an updated version of the original Cochrane
Review published in Issue 3, 2008.
Objectives
To determine the effect of altered radiation fraction size on outcomes for women with early breast cancer who have undergone breast
conserving surgery.
Search methods
We searched the Cochrane Breast Cancer Group Specialised Register, MEDLINE, EMBASE and the WHO ICTRP search portal to
June 2009, reference lists of articles and relevant conference proceedings. We applied no language constraints.
Selection criteria
Randomised controlled trials of unconventional versus conventional fractionation inwomenwith early breast cancer who had undergone
breast conserving surgery.
Data collection and analysis
The authors performed data extraction independently, with disagreements resolved by discussion. We sought missing data from trial
authors.
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Main results
Four trials reported on 7095 women. The women were highly selected: tumours were node negative and 89.8% were smaller than 3
cm. Where the breast size was known, 87% had small or medium breasts. The studies were of low to medium quality. Unconventional
fractionation (delivering radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not
affect: (1) local recurrence risk ratio (RR) 0.97 (95% CI 0.76 to 1.22, P = 0.78), (2) breast appearance RR 1.17 (95% CI 0.98 to 1.39,
P = 0.09), (3) survival at five years RR 0.89 (95% CI 0.77 to 1.04, P = 0.16). Acute skin toxicity was decreased with unconventional
fractionation: RR 0.21 (95% CI 0.07 to 0.64, P = 0.007).
Authors’ conclusions
Two new studies have been published since the last version of the review, altering our conclusions. We have evidence from four low to
medium quality randomised trials that using unconventional fractionation regimens (greater than 2 Gy per fraction) does not affect
local recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance or late toxicity for selected
women treated with breast conserving therapy. These are mostly women with node negative tumours smaller than 3 cm and negative
pathological margins. Long-term follow up (> 5 years) is available for a small proportion of the patients randomised. Longer follow up
is required for a more complete assessment of the effect of altered fractionation.
P L A I N L A N G U A G E S U M M A R Y
Fraction size in radiation treatment for breast conservation in early breast cancer
Breast cancer is an important disease for women, with one in eight women in the United States and Australia and one in nine women
in the United Kingdom being diagnosed with the condition by age 85 years. Breast conserving therapy (removing the tumour but
keeping an intact breast) has proven to be as effective as mastectomy (removing the breast tissue) in terms of survival for women with
cancer confined to the breast (or the local lymph nodes, or both), as long as a five to six-week course of radiation therapy is delivered.
This involves 25 to 30 visits to a radiation oncology department. Without radiation therapy after breast conserving surgery there is a
significant risk of breast cancer returning in the breast (local recurrence) in as many as 30 to 40 women per 100. Furthermore, for every
local recurrence avoided with radiation, one death is avoided at 15 years. Many women prefer breast conservation which has resulted
in an increased demand for radiation services. Giving fewer radiation treatments (fractions) would be beneficial to women if this has
the same effect on tumour control and survival and cosmetic outcome. In order to reduce the number of treatments, the radiation dose
delivered per fraction is increased. This may also reduce demand on radiation resources and be more convenient for women.
Four trials, involving 7095 women, were included in this review. Local recurrence was not significantly different for women having
fewer treatments. Breast appearance was not significantly different for women undergoing fewer treatments. Survival was not altered by
having fewer treatments and there was no significant difference in late skin toxicity or radiation toxicity. Acute skin toxicity is decreased
with fewer treatments. Most of the women in the trials (89.8%) had tumours less than 3 cm in size, all had complete removal of the
tumour on pathology and 79% had no evidence of cancer in their lymph nodes. Where the breast size was known, 87% had small or
medium breasts. This review indicates that for women who fit these criteria, using fewer radiation treatments after tumour removal is a
safe and effective option. Long-term follow up (> 5 years) is available for a small proportion of the total number of patients randomised.
Ongoing follow up is required for a more complete assessment of the impact of larger than standard fraction size on local recurrence
rates, toxicity and breast appearance.
B A C K G R O U N D
Description of the condition
This review is an update of a review previously published in The
Cochrane Database of Systematic Reviews (Issue 3, 2008) on frac-
tion size in radiation treatment for breast conservation in early
breast cancer. Breast cancer is the most common cancer diagnosed
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in women and the second most common cause of cancer death in
women. The lifetime risk to age 85 years of being diagnosed with
breast cancer for women living in Australia and the United States
is one in eight, and one in nine for women living in the United
Kingdom (AIHW 2006; ONS 1999; Ries 2004).
A significant change has occurred in the management of women
with early breast cancer (cancer confined to the breast and nearby
lymph nodes) over the last three decades. Previously most women
with early breast cancer underwent removal of the whole breast
(mastectomy). Evidence from several randomised controlled tri-
als (Fisher 1989; Veronesi 1990) and a meta-analysis of 36 tri-
als (EBCTCG 1995) confirms that long-term overall survival is
equivalent using breast conserving treatment compared with mas-
tectomy. Breast conserving treatment comprises removal of the
portion of the breast containing the tumour followed by radiation
treatment to the remaining breast tissue.Other studies have shown
that quality of life is enhanced in women who undergo breast
conserving treatment (Al-Ghazal 2000). Consequently, breast
conserving treatment has become the recommended option for
womenwith early breast cancer inmanywestern countries (NBCC
2001; NIH 1991). Breast conserving surgery now accounts for
70% of breast cancer operations in some series (Chouillet 1994)
and, as a result, demand for radiation treatment services has in-
creased. Some health services have struggled to meet this increas-
ing demand because of a shortage of trained personnel and expen-
sive radiation treatment machines (Ash 2000; Mackillop 1994).
Description of the intervention
Radiation following breast conserving surgery involves treatment
to the breast with ionising radiation. Typically the radiation is
delivered over a period of five to six weeks using a standard 2 Gy
(Gray) radiation dose per fraction, in 25 to 30 treatment episodes,
to a total dose of 50 to 60 Gy.
Recently there has been interest from cancer service providers in
shortening the overall treatment time. One method of achieving
this is to increase the size of each fraction thereby decreasing the
total number of fractions required. For example, case series using
40 Gy in 15 fractions or 36 Gy in 12 fractions have been reported
(Ash 2000; Olivotto 1996). Shorter fractionation schedules have
the advantages of using machine and staff time more efficiently
and reducing patient inconvenience.
Concerns have been raised, however, as to whether shorter frac-
tionation schedules have equivalent outcomes in terms of local
tumour control, breast appearance (cosmesis), late toxicity, overall
survival and patient satisfaction. The concern with larger fraction
sizes is based on radiobiological principles which state that the
fraction size is the dominant factor in determining late side ef-
fects. The aim of conventional fractionation at 2 Gy per fraction
is to decrease the rate of late tissue damage whilst aiming to max-
imise tumour control with acceptable acute toxicity (Hall 1994).
Higher fraction size could lead to increased scarring and retraction
of breast tissue as well as skin atrophy (thinning) and telangiectasia
(dilated blood vessels).
Why it is important to do this review
The optimal fractionation schedule is not well-established (
Whelan 1993) but evidence from clinical trials suggests that the
results of shorter schedules may be equivalent with respect to local
control and cosmesis (Whelan 2000; Yarnold 1994). Published
trials to date have been too small to detect differences in cancer
recurrence rates reliably.
If a shorter fractionation schedule was shown to provide equiva-
lent outcomes for women this could lead to more efficient use of
radiation services and more expedient treatment for patients.
O B J E C T I V E S
To determine the effect of altered radiation fraction size on out-
comes for women with early breast cancer who have undergone
breast conserving surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were considered for inclusion.
We required the comparisons to be unconfounded, that is the treat-
ment given to the intervention and comparator groups could dif-
fer only in relation to the fractionation schedule used. Trials where
the participants received adjuvant treatment in the form of che-
motherapy, monoclonal antibody treatment, or hormonal therapy
were eligible providing these treatments were applied equally to
all study groups. Published and unpublished studies were eligible.
Types of participants
Women with histologically confirmed early breast cancer who had
undergone breast conserving surgery. Early breast cancer is de-
fined as invasive adenocarcinoma restricted to the breast, plus or
minus the local lymph nodes, which can be removed surgically
(EBCTCG 2002), that is T1-2, N0-1, M0 (Fleming 1997).
Surgery could include lumpectomy, wide local excision, quadran-
tectomy, or segmental resection; with or without axillary dissec-
tion, node sampling, or sentinel node biopsy.
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Types of interventions
Postoperative radiation to the breast alone and delivered using con-
ventional fractionation (1.8 to 2 Gy per fraction) versus postoper-
ative radiation to the breast alone at greater than 2Gy per fraction.
In order to compare the differing dose schedules we converted frac-
tionation schedules to biologically equivalent doses (BED). The
dose prescribed and the prescription point had to be clearly iden-
tified. We specified the dose in accordance with the International
Commission on Radiation Units and Measurements (ICRU 50)
recommendations with respect to dose, dose specification point
and dose per fraction. Where possible, we converted data found
in studies into this form.
Types of outcome measures
Primary outcomes
1. Local recurrence in the ipsilateral breast (i.e. the same breast
where the cancer had been diagnosed).
2. Appearance or cosmesis (objective and subjective) of the
treated breast.
Secondary outcomes
1. Overall survival (time from date of randomisation to death
from any cause, or number of deaths from any cause).
2. Toxicity (including acute and late effects of radiation
therapy and chemotherapy-related toxicity); individual protocol-
based definitions were used.
3. Cancer-specific mortality.
4. Relapse-free survival.
5. Mastectomy rate (following local recurrence).
6. Quality of life (trial-specific instruments).
7. Costs (to women and health services).
Search methods for identification of studies
We searched the Cochrane Breast Cancer Group Specialised Reg-
ister (23 June 2009). The details of search strategies used by the
Group for the identification of studies and the procedure used to
code references are outlined in their module (Breast Cancer Group
2009).We extracted studies coded as ’early’ and ’radiotherapy’ and
’dose intensity’ in the Specialised Register for consideration.
In addition, we conducted a comprehensive search of MEDLINE
(OVID) (1966 to August 2009) (see Appendix 1) and EMBASE
(OVID) (1980 to August 2009) (see Appendix 2).
We also searched the WHO International Clinical Trials Registry
Platform (ICTRP) Search Portal (performed search 10 June 2010
for the period until 23 June 2009; http://apps.who.int/trialsearch/
) (see Appendix 3).
Searches were not limited by language or date.
Data collection and analysis
Selection of studies
All four original authors checked the titles and abstracts retrieved
by the searches. BH did so for the repeated search. Each author
independently assessed the full text of all studies we thought rele-
vant to the review with differences being resolved by discussion.
Data extraction and management
Two authors (BH and ML) performed data extraction indepen-
dently, with disagreements being resolved by discussion. We en-
tered data intoRevMan5 (RevMan 2008) for analysis.Where data
were limited, we requested further information from the authors
of the original studies (with data requested at five-year follow up
to allow comparison between trials). We received data from the
authors of STARTA 2008, STARTB 2008 and Owen 2006. Data
for local recurrence for Owen 2006, START A 2008 and START
B 2008 were available from two sources; the authors (at five years
follow up to allow comparison with data from other studies) and
extracted from the paper (with slightly different lengths of follow
up - see Characteristics of included studies). Data for local recur-
rence events was derived from percentages (Whelan 2002) where
raw numbers were not available (we assumed the denominators
used were the numbers in each arm of the trial). We calculated the
log rank statistic (O-E) and its variance for START B 2008 and
Whelan 2002 using an Excel spreadsheet developed by Matthew
Sydes (Cancer Division) in collaboration with the Meta-analysis
Group of theMRCClinical TrialsUnit, London (Sydes 2007). For
START B 2008, the report presented hazard ratios (HR), number
of events in each arm and the randomisation ratio was 1:1, so we
used these to derive the log rank statistic (O-E) and its variance
(Sydes 2007). For Whelan 2002, data from the curve were pre-
sented with numbers at risk, so we used these to derive the log
rank statistic (O-E) and its variance (Sydes 2007). For relapse-free
survival (Whelan 2002), numbers at risk were given, so we de-
rived the log rank statistic (O-E) and its variance from the survival
curves (Sydes 2007).
Assessment of risk of bias in included studies
Two review authors (BH, ML) categorised the risk of bias of each
eligible study using the system outlined in theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2008). DF resolved
any discrepancies which arose. Risk of bias tables were constructed
(constructed by BH, and reviewed byML), with any discrepancies
resolved by discussion for the included studies. We constructed a
’Risk of bias’ graph with review authors’ judgements about each
methodological quality item (presented as percentages across all
included studies) (see Figure 1).
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Weplanned sensitivity analysis on the basis of study quality, which
was to be performedwith andwithout trials of low quality to assess
the effect of quality on the results. This was not possible with only
four included trials.
Measures of treatment effect
Summary statistics for dichotomous measures were presented as
risk ratios (RR) with 95% confidence intervals (CI) (Deeks 2003).
Summary statistics for continuous variables were presented as
meandifferences (MD),where possible.WeusedMantel-Haenszel
methods to calculate pooled risk ratios (Greenland 1985; Mantel
1959). For the endpoints local recurrence at five years and survival
at five years, we also derived the log rank statistic (O-E) and its
variance where possible (START B 2008; Whelan 2002).
Data synthesis (meta-analysis)
We applied the intention-to-treat principle in analysing data from
the trials and determined a weighted average treatment effect us-
ing the fixed-effect model to combine results (Mantel 1959) in
RevMan 5. Where the log rank statistic (O-E) and its variance
were available for the endpoint local recurrence (START B 2008;
Whelan 2002), survival (START B 2008; Whelan 2002) and re-
lapse-free survival (Whelan 2002) we used Peto’s method to esti-
mate the pooled hazard ratio (HR). Our comparison of interest
was unconventional fractionation versus conventional fractiona-
tion, so when analysing the trials we combined the two different
’fractionation dose’ unconventional arms of the Owen 2006 and
START A 2008 trials as described in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2008). In the future, if
more information becomes available, separate analysis may be pos-
sible to investigate a dose effect for different fractionation sched-
ules.
Cosmesis outcomes were dichotomised in the reports so we re-
ported the results as RRs. For late skin toxicity, we converted per-
centages given in the text to numbers and reported a RR (as there
were data from one trial only (Whelan 2002).
Global cosmetic outcome (appearance) was reported for 735
women at five years (Whelan 2002) as a dichotomised outcome.
We used the four-point European Organisation for Research
and Treatment of Cancer (EORTC) Cosmetic Rating System
(Aaronson 1988) and dichotomised the results as good or excellent
versus poor or fair (see additional Table 1).
Acute radiation toxicity:
1. Acute skin toxicity was reported for START A 2008 and
START B 2008.
Late radiation toxicity:
1. Skin toxicity (Whelan 2002) was assessed at five years using
a five-point scale (Winchester 1992) (see additional Table 2) and
analysed as a dichotomous outcome using RR. The results were
dichotomised into: none or mild versus moderate, marked or
severe.
2. Ischaemic heart disease for women with left-sided tumours
(at median follow up five-six years) was reported in full (START
A 2008; START B 2008).
3. Rib fractures (at median follow up five-six years) were
reported in full (START A 2008; START B 2008).
4. Induration (fibrosis) and subcutaneous toxicity:
We assumed that induration and subcutaneous toxicity (at five
years), reported by Owen 2006 and Whelan 2002 respectively,
represented the same outcome and could, therefore, be combined
for analysis. Whelan 2002 used the RTOG/EORTC five-point
late radiation morbidity scale (Winchester 1992) (see Additional
Table 2) and Owen 2006 used a four-point trial-specific scale
(see Additional Table 3). No patient in Whelan 2002 had severe
(Grade 4) toxicity. The results were dichotomised in the Owen
2006 report but reported in full in Whelan 2002. In order to
combine the results, we dichotomised the Whelan 2002 results
into two groups: those with nil or slight late radiation toxicity, and
those who had any greater toxicity; that is the women who had
scores of two or more were counted as having toxicity.
Marked or any change in breast appearance: results were di-
chotomised in the report (Owen 2006).
If sufficient data become available in future updates we will use
recommended methods to collect and combine the data. We will
use the mean difference method unless trials have reported results
on different scales, in which case we will use a standardised mean
difference to summarise data (Deeks 2003).
Subgroup analysis and investigation of heterogeneity
The current version of the review does not contain any subgroup
analyses because of the lack of data. However, if sufficient data
become available in future updates we may perform subgroup
analyses to investigate whether the effects of different radiation
fraction schedules differ depending on nodal status, margin status,
hormone receptor status, and tumour stage or other factors which
may become relevant in the future.
We assessed heterogeneity both visually and statistically using the
Chi2 test (Altman 1992;Walker 1988) and the Higgins I2 statistic
(Higgins 2002; Higgins 2003).
Radiation doses were converted to the biological equivalent dose
(BED), where BED = nd (1+d/alpha/beta) (Fowler 1989; Steel
1997). This was to facilitate comparison of radiation doses given at
differing dose per fraction. The value of alpha/beta used for breast
tumour cells was four (Steel 1997; Thames 1987;Williams 1985).
Using these values, we aimed to compare those studies with a BED
< 75 and a BED > 75. Brachytherapy (radiation sources applied
directly to the body) would be converted toBEDusing themethod
of Stitt (Stitt 1992; Yamada 1999). For brachytherapy we recorded
data, where possible, in the form of dose, dose specification point,
plane of interest (for example at 1 cm from the central plane),
mean central dose and peripheral dose.
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R E S U L T S
Description of studies
We screened a total of 2284 abstracts, and considered 67 papers
in full for eligibility. We excluded 48 (see table Characteristics of
excluded studies).
The 18 reports that met the inclusion criteria (Anon 1997; Clarke
1996; OCOG 1992; Owen 2006; START A 2008; START B
2008; Sumo 2008; Whelan 2000; Whelan 2002; Whelan 2008;
Yarnold 1992; Yarnold 1993; Yarnold 1994; Yarnold 1994a;
Yarnold 2000; Yarnold 2001; Yarnold 2005; Yarnold 2005a) re-
lated to four separate studies (Owen 2006; START A 2008;
START B 2008; Whelan 2002). All of the trials had published
their results at different times with different periods of follow up.
We used the most recent publication as the source for the review,
supplementing this with information from earlier reports if nec-
essary. Thus, for the Owen 2006 trial the primary source is Owen
2006, with nine other publications found for this trial (Anon
1997; Yarnold 1992; Yarnold 1993; Yarnold 1994; Yarnold 1994a;
Yarnold 2000; Yarnold 2001; Yarnold 2005; Yarnold 2005a). The
primary source for the second trial was Whelan 2002, with four
other publications found (Clarke 1996; OCOG 1992; Whelan
2000; Whelan 2008). For START A 2008, one other publication
was found (Sumo 2008), which also referred to START B 2008.
The four randomised trials included in this current version of the
review involved a total of 7095 women.
Whelan 2002 was a randomised controlled trial comparing two
different fractionation regimens (42.5 Gy in 16 fractions and 50
Gy in 25 fractions). The trial was multi-centred with patients
recruited from tertiary institutions. This study included 1234
womenwith node negative, invasive breast cancerwhowere treated
with lumpectomy and had negative pathological margins. Patients
with large breasts (defined as a cup size separation of greater than
25 cm, that is the breast measured greater than 25 cm left to right
at its widest part) were excluded. The primary outcome measure
was local recurrence of invasive breast cancer in the treated breast.
The trial reported breast appearance and late radiation toxicity
but did not assess costs or quality of life. The five-point Radi-
ation Oncology Group/ EORTC late radiation morbidity scale
(Winchester 1992) was used to report skin toxicity (additional
Table 2). Global cosmetic outcome was assessed by trained clin-
ical trials nurses using the four-point European Organisation for
Research and Treatment of Cancer (EORTC) Cosmetic Rating
System (additional Table 1). 1220/1234(98.8%) of the women
in the trial had baseline cosmetic assessment. Cosmetic outcome
was assessed in the 735/1220 women with five years follow up at
the time of assessment. No women were treated with boosts (extra
dose delivered to the tumour bed) (see additional Table 4).
More detail is available in the table Characteristics of included
studies.
The second study (Owen 2006) was a randomised controlled trial
comparing three fractionation regimens (39 Gy in 13 fractions,
42.9 Gy in 13 fractions, and 50 Gy in 25 fractions). The trial
was multi-centred in a tertiary setting. The study included 1410
women with invasive breast cancer who were treated with breast
conserving surgery and had negative pathological margins. The
primary outcome measure was late change in breast appearance.
Late change in breast appearance was assessed in the 1202 women
who had photographs available at baseline and at least a single
follow up. Pairs of photographs were available as follows: 1128 at
year one, 1004 at year two, 525 at three years, 472 at four years,
765 at five years and 141 at 10 years, i.e. photographic follow
up was reported for 63% of women at five years, and 11% at 10
years. The trial reported both cosmesis and late radiation toxicity
but did not assess costs or quality of life. Cosmesis (appearance)
was assessed clinically in the first 806 women at annual follow-up
visits; clinicians used a four-point scale (Additional Table 5). We
have no evidence that these women were substantially different
to the remainder of women in the trial: the reasons that women
were not followed were not related to which arm they were ran-
domised to and were not related to whether they had local relapse
or late normal tissue side-effects from treatment. Quote: “Reasons
for non-availability were explored, and no evidence was observed
that this was associated with either the fractionation schedule or
to the probability of experiencing future normal tissue event or lo-
cal relapse (Owen 2006).” The clinical assessment results were di-
chotomised in the report into fair or poor versus good or excellent
(Owen 2006). Of women enrolled, 1051 (75%) were treated with
a boost of 14 Gy at 90% in seven fractions. The authors did not
report howmany women in each arm received a boost. For women
with negative margins, if the clinician felt it was appropriate, there
was a sub-randomisation to boost or no boost from January 1986
to May 1994. After this, all 687 patients were offered an elective
boost (see additional Table 4).
START A 2008 was a randomised trial comparing three fractiona-
tion regimens (41.6 Gy in 13 fractions, 39 Gy in 13 fractions and
50 Gy in 25 fractions). The trial was multi-centred in a tertiary
setting. The study included 2236 women with invasive breast can-
cer, 85% of them were treated with breast conserving surgery, and
all had negative pathological margins. The primary outcome mea-
sures were loco-regional relapse, normal tissue effects and quality
of life. The trial reported cosmesis and late radiation toxicity.Qual-
ity of life and economic consequences (which were not defined)
will be reported separately for women from 13 centres participat-
ing in START A 2008. Late change in breast appearance (photo-
graphic) was assessed in the 1055 women who had both a photo
at baseline and a follow-up photo. Not all patients had a photo at
five years. Those with photos at two and five years were combined
when reported, and the authors did not report howmany had five-
year follow up. We have no evidence that these women were sub-
stantially different to the remainder of women in the trial. Quote:
“There were no associations between score for change in breast
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appearance (photographic) at two years or patient demographic or
treatment characteristics and whether or not the patient had a five-
year assessment (data not shown)” (START A 2008). For women
treated with breast conservation, 771/1269 (61%) of women in
the experimental arm and 381/631 (60%) of women in the con-
trol arm received a boost of 10 Gy in five fractions using electrons.
In total, 1152/1900 (61%) received a boost. Each participating
department specified in advance whether patients enrolled from
that site would receive radiotherapy boost (see additional Table 4).
START B 2008 was a randomised trial comparing two fraction-
ation regimens (40 Gy in 15 fractions and 50 Gy in 25 frac-
tions). The trial was multi-centred in a tertiary setting. The study
included 2215 women with invasive breast cancer; 2038/2215
(92%) of them were treated with breast conserving surgery, and
all had negative pathological margins. The primary outcome mea-
sures were loco-regional relapse, normal tissue effects and quality
of life. The trial reported cosmesis and late radiation toxicity.Qual-
ity of life and economic consequences (which were not defined)
will be reported separately. Late change in breast appearance (pho-
tographic) was assessed in the 923 women who had both a photo
at baseline and a follow-up photo. Not all patients had a photo at
five years; those with photos at two and five years were combined
when reported and the authors did not report how many had five-
year follow up. Quote: “There were no associations between score
for change in breast appearance (photographic) at two years or pa-
tient demographic or treatment characteristics and whether or not
the patient had a five-year assessment (data not shown)”.(START
B 2008). Quote: “We have no evidence that these women were
substantially different to the remainder of women in the trial”. For
women treated with breast conservation, 446/1018 (44%) and
422/1020 (41%) received a 10 Gy on five fraction boost using
electrons. In total, 868/2038 (43%) received a boost. Each partic-
ipating department specified in advance whether patients enrolled
from that site would receive radiotherapy boost (see additional
Table 4).
More detail is available in the table Characteristics of included
studies.
Risk of bias in included studies
See ’Risk of bias’ tables (Figure 1).
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Sequence generation was adequate: three trials were randomised
(START A 2008; START B 2008;Whelan 2002), for Owen 2006
this was unclear. We know for START A 2008, START B 2008
and Whelan 2002 that this allocation was computer-generated.
Concealment of allocation was adequate: for Owen 2006, START
A 2008 and START B 2008 the authors state that “randomisa-
tionwas not blinded”. Computer-generated permuted blocks were
used in START A 2008 and START B 2008, which may allow
prediction of the next randomisation in the sequence. If those
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undertaking recruitment are not aware that permuted blocks are
being used, or the block size, then this should not distort the re-
cruitment. In Whelan 2002 the process was central, although not
explicitly described as concealed.
Blinding
For subjective outcomes, in Owen 2006, START A 2008, START
B 2008 and Whelan 2002 the patients and personnel were not
mentioned as blinded (unlikely to have impact on risk of bias).
The assessors for photographic appearance (Owen 2006; START
A 2008; START B 2008) were blinded which was most important
for assessment of this subjective primary outcome. Clinical assess-
ments were not blinded (Owen 2006), although they were done
by many people, which may potentially reduce the risk of bias.
For objective outcomes: blindingwas notmentioned (Owen 2006;
START A 2008; START B 2008; Whelan 2002), therefore was
probably not done. The time points for clinical examinations were
pre-specified, but the timing for mammography was not reported
(Owen 2006; START A 2008; START B 2008). Any lead time
bias in diagnosis of local recurrence by un-blinded clinical assessors
would be reduced by the pre-specifiedmammography and clinical
examination intervals inWhelan 2002, it was unclear whether this
was the case for Owen 2006; START A 2008 and START B 2008.
Incomplete outcome data
For Owen 2006 there were explicit details given with respect to
the numbers lost to follow up and the reasons (per treatment
arm) given. Attrition was clearly described in START A 2008
and START B 2008. In Whelan 2002 there is no detail given
regarding attrition, which is a potential source of bias. In Owen
2006, 1202/1410 women had photos at both baseline and at a
later time point for the subjective cosmetic and toxicity outcomes
assessment. Reasons for attrition were not detailed, which is a
potential source of bias. In START A 2008 1306/2236 enrolled
in the photographic study: assessed in 1055 patients with both a
baseline and a follow-up photograph. In START B 2008 1094/
2215 enrolled in the photographic study. For both START A
2008 and START B 2008 it is not clear why not all patients were
enrolled, a source of possible bias.
Cosmetic outcome was assessed in 735/1220 women; those who
had follow up to five years at the time of the initial trial report
(Whelan 2002). It may be that the reason others did not have
five years follow up is because they had not been in the trial long
enough, but it could also potentially be due to other reasons, per-
haps because of withdrawal or non-attendance, a possible source
of bias.
Late radiation toxicity was assessed in 752/1220 women at five
years. It may be that not all women had five years follow up, but
this is not made clear (Whelan 2002). The authors make the point
that most of the toxic effects of radiotherapy are evident by five
years follow up.
For quality of life, the first 806/1410 women were selected to enrol
in the prospectively collected physician assessments (START A
2008). In START B 2008, 1079/2215 enrolled in the quality of
life study. It is not clear how the patients enrolled in the quality of
life study were selected in both studies (START A 2008; START
B 2008).
Selective reporting
For all four trials the majority of outcomes detailed in the meth-
ods were reported. For START A 2008 and START B 2008 the
health economics consequences have not been reported. Without
comparing the reports with the trial protocols, we could not be
sure all outcomes were reported.
Other potential sources of bias
All studies were potentially biased by early reporting: Owen 2006
reported “minimum 5 year follow up” for the subjective primary
outcome. The trial was stopped early because the START trials
started. For the subjective outcome assessed photographically in
both START A 2008 and START B 2008, not all women were
assessed at five years, so it is possible that only a small number of
women were assessed with five years follow up. In Whelan 2002
not all women had five years follow up at the time of reporting.
Effects of interventions
Four trials enrolling 7095 women were included in the review. In
the results presented here, ratios of treatment effects are given such
that RRs < 1.0 would indicate a beneficial effect of unconventional
fractionation over conventional fractionation (although, as noted
below, most of these results were not statistically significant).
Primary outcomes
Ipsilateral local recurrence
Overall, 271 local recurrences in 7095 women were reported at
five years.
In the Owen 2006 study, 106 local recurrences in 1410 women
were reported at five years: 71 in the unconventional arm and 35
in the conventional arm. In STARTA 2008, data from the authors
reported 74 local recurrences in 2236 women at five years: 52 in
the combined unconventional arms and 22 in the conventional
arm. Extraction of results from the paper STARTA 2008 reported
84 local recurrences at median 5.1 years; 59 in the combined un-
conventional arms and 25 in the conventional arm. In START
B 2008, data from the authors reported 53 local recurrences in
2215 women at five years: 20 in the unconventional arm and 33
in the conventional arm. In the paper START B 2008, 59 local
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recurrences were reported at median 6.0 years: 25 in the uncon-
ventional arm and 34 in the conventional arm. In the Whelan
2002 study, 38 local recurrences were reported in 1234 women at
5 years; 18 in the unconventional arm and 20 in the conventional
arm.
Local recurrence was evaluated in two ways: 1) using slightly dif-
ferent lengths of follow up, i.e. at five years incorporating raw data
from the authors (Owen 2006; START A 2008; START B 2008;
Whelan 2002) and using data extracted from the paper (Owen
2006; START A 2008; START B 2008; Whelan 2002) (median
follow up 5.1 to 8.1 years) and 2) reported as Hazard Ratio (HR)
from the derived O-E and variance (START B 2008; Whelan
2002).
1. Local recurrence at five years (Owen 2006; START A 2008;
START B 2008; Whelan 2002): risk ratio (RR) 0.93 (95% CI
0.73 to 1.19, P = 0.55). The test for heterogeneity (I2 = 16%, P
= 0.31) suggests that there is no significant heterogeneity
(Analysis 1.1).
2. Local recurrence at five years calculated using data extracted
from the papers, with longer follow up (Owen 2006; START A
2008; START B 2008; Whelan 2002 ): RR 0.97 (95% CI 0.76
to 1.22, P = 0.78). The test for heterogeneity (I2 = 0%, P = 0.56)
suggests that there is no significant heterogeneity (Analysis 1.2).
3. Local recurrence at five years using log rank statistic (O-E)
and its variance: HR 0.93 (95% CI 0.63 to 1.38, P = 0.72). The
test for heterogeneity (I2 = 56%, P = 0.13) indicates that there is
unlikely to be heterogeneity, as the confidence intervals overlap
and P value is greater than 0.10 (Analysis 1.3).
4. Local recurrence at 10 years: RR 0.99 (95% CI 0.77 to
1.29, P = 0.96) (Owen 2006; Whelan 2002). The test for
heterogeneity (I2= 0%, P = 0.72) indicates no significant
heterogeneity (Analysis 1.4).
Appearance (objective and subjective) of the post-treatment
breast (cosmesis)
Data were available from all trials but not in a form which could
be combined in analysis.
Global cosmetic outcomewas reported for 735women at five years
(Whelan 2002). The triallists performed cosmetic assessment on
1220 women at baseline and had complete cosmetic data on 735
women at five years (the time of interest for the outcome).We have
no indication that these women were different to the remainder of
those randomised. A four-point scale (Aaronson 1988) was used
and the results were dichotomised as good or excellent versus poor
or fair. These results were reported as percentages at three and five
years with the total number of women available for evaluation at
each time period; as we did not know the numbers in each arm,
we were unable to derive figures from these data. At five years,
the percentage of patients with good or excellent global cosmetic
outcome was 76.8% in the altered fractionation arm and 77.4%
in the conventional fractionation arm (absolute difference -0.6%,
95%CI -6.5% to5.5%), P value not reported; figures from the text
(Whelan 2002). At median follow up of 12 years, the percentage
of patients with good or excellent global cosmetic outcome was
70% in the altered fractionation arm and 71% in the conventional
arm (absolute difference 1.5%; 95% CI -6.9% to 9.8%, P value
not reported); figures from the text (Whelan 2002).
Owen 2006 reported breast cosmesis (median follow up of 8.1
years, maximum 15 years) using a four-point scale (see additional
Table 5). A total of 806 women (see Description of studies) were
assessed and the results were reported for a dichotomous outcome
in the report. Of 535 women in the altered fractionation arm,
244 (41.8%) were scored as having a good or excellent result and
106 of 271 (39.1%) in the conventional fractionation arm had a
good or excellent result (figures derived from the text): RR 1.17
(95% CI 0.98 to 1.39, P = 0.09). Testing for heterogeneity was
not applicable (Analysis 1.5).
START A 2008 reported photographic assessment of change in
breast appearance for those women treated with breast conserving
surgery (median follow up of 6.0 years, maximum 6.2 years) using
a three-point scale. A total of 1055 women (see Description of
studies) were assessed at a mix of two and five years and were
dichotomised into mild or marked change or no change (figures
reported from text). For comparison of 41.6 Gy versus 50 Gy:
hazard ratio (HR) 1.09 (95% CI 0.85 to 1.40, P = 0.62). For
comparison of 39 Gy versus 50 Gy: HR 0.69 (95% CI 0.52 to
0.91, P = 0.01).
START B 2008 reported photographic assessment of change in
breast appearance for those women treated with breast conserving
surgery (median follow up of 5.1 years, maximum 6.0 years) using
a three-point scale. A total of 923 women (see Description of
studies) were assessed at a mix of two and five years and were
dichotomised into mild or marked change or no change (figures
reported from text): HR 0.83 (95% CI 0.66 to 1.04, P = 0.06).
Owen 2006 reported minimum five-year follow up for any or
marked change in breast appearance and found no significant dif-
ference between the unconventional and conventional arms for
any change: RR 1.01 (95% CI 0.88 to 1.17, P = 0.86) or for
marked change: RR 1.24 (95% CI 0.77 to 2.00, P = 0.37). There
was no difference inmoderate ormarked breast distortion between
the two trial arms: RR 1.01 (95% CI 0.87 to 1.17, P = 0.90).
Secondary outcomes
1. Overall survival
(Time from date of randomisation to death from any cause, or
number of deaths from any cause at five years).
The RR was 0.89 (95% CI 0.77 to 1.04, P = 0.16) (START A
2008; STARTB2008;Whelan2002). The test for heterogeneity (I
2 = 28%, P = 0.25) indicates no significant heterogeneity (Analysis
1.6).
9Fraction size in radiation treatment for breast conservation in early breast cancer (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For deaths at five years the hazard ratio (HR) was 0.81 (95% CI
0.65 to 1.00, P = 0.05) (START B 2008; Whelan 2002). The
test for heterogeneity (I2 = 0%, P = 0.36)indicates no significant
heterogeneity (Analysis 1.7).
2. Toxicity
(Including acute and late effects of radiation therapy, and chemo-
therapy-related toxicity).
Individual protocol-based definitions were used. Toxicity and late
effects were reported on assessable numbers.
Acute radiation toxicity
Acute radiation toxicity was significantly decreased in the uncon-
ventional arm: RR 0.21 (95% CI 0.07 to 0.64, P = 0.007) (I2 =
0%, P = 0.62). There was no significant heterogeneity (START A
2008; START B 2008) (Analysis 1.8).
Late radiation toxicity
1. Late skin toxicity: skin toxicity at five years (Whelan 2002)
was assessed using the Radiation Oncology Group/EORTC late
radiation morbidity scale (Winchester 1992), which has a five-
point scale (see additional Table 2). No woman had severe
(Grade 4) skin toxicity: RR 0.99 (95% CI 0.44 to 2.22, P =
0.98). A test for heterogeneity was not applicable with only one
trial. At five years 3% in both the experimental and control arms
had moderate/severe skin toxicity. Whelan 2002 reported at 10
years, that 6% of those in the unconventional arm had
moderate/severe late skin toxicity versus 3% in the conventional
arm “no differences detected”, no P value given, figures from
text) (Whelan 2002).
2. Late radiation subcutaneous toxicity at five years: RR 1.00
(95% CI 0.81 to 1.24, P = 0.99). There was no heterogeneity (I2
= 36%, P = 0.21) (Owen 2006; Whelan 2002) (Analysis 1.10).
Late radiation subcutaneous toxicity at 10 years: moderate/severe
subcutaneous toxicity was reported for 8% in the
unconventionally fractionated arm, versus 4% in the
conventional fractionation arm (“no differences detected”, no P
value given) (Whelan 2002).
3. Ischaemic heart disease (in women with left-sided
tumours): RR 1.07 (95% CI 0.32 to 3.56, P = 0.91). There was
no heterogeneity (I2 = 0%, P = 0.47) (Analysis 1.11) (START A
2008; START B 2008).
4. Rib fractures: RR 0.93 (95% CI 0.25 to 3.41, P = 0.92).
There was no heterogeneity (I2 = 0%, P = 0.74) (Analysis 1.12)
(START A 2008; START B 2008; Whelan 2002).
3. Cancer specific mortality
No data.
4. Relapse-free survival
Data available for Whelan 2002 at five years: RR 1.10 (95% CI
0.81 to 1.49, P = 0.37).
5. Mastectomy rate
No data.
6. Quality of life (trial-specific instruments)
No data.
7. Costs (to women and health services)
No data.
D I S C U S S I O N
For women with early breast cancer, achieving and maintaining
local control in addition to maximising survival are the main goals
of management.Whilst conservative surgery followed by radiation
therapy allows preservation of the breast, the requirement for five
to six weeks of radiation therapy, which may only be available at
some distance from the woman’s residence, can be a burden. The
many costs involved (monetary and other) may mean that women
choose mastectomy over breast conserving therapy to avoid the
necessity for radiation therapy (Nattinger 2001).
Shortening the duration of postoperative breast radiation would
provide the advantage of shorter disruption of normal activities
and less time away from home and family. Reducing the number
of fractions required would also free up radiation therapy machine
time. This may reduce waiting lists and improve timely access
to radiation therapy for other patients with cancer. The ability
to reduce the number of fractions required to treat women with
early breast cancer safely may, therefore, result in many benefits
at a personal, national and international level provided acceptable
local control, toxicity and survival can be maintained with this
approach.
This review set out to explore whether shortened (altered fraction-
ation) regimens used to treat women who have had conservative
surgery for early breast cancer can offer the same tumour control
and cosmetic results as longer fractionation regimens. We have
been able to include data from four randomised controlled trials
that compared different fractionation schemes. The comparison
studied is altered fractionation (fraction size greater than 2 Gy)
versus conventional fractionation (2 Gy per fraction).
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Local control
For these comparisons, there appears to be no difference between
the fractionation techniques for local control:
1. At five years, when the data from the authors is used: RR
0.93 (95% CI 0.73 to 1.19, P = 0.55) (Analysis 1.1), when data
are extracted from the paper: RR 0.97 (95% CI 0.76 to 1.22, P =
0.78) (Analysis 1.2) and hazard ratio 0.93 (95% CI 0.63 to 1.38,
P = 0.72) (Analysis 1.3).
2. At 10 years: RR 0.99 (95% CI 0.77 to 1.29, P = 0.96)
(Analysis 1.4).
Breast appearance (cosmesis)
For this comparison, although studies could not be combined,
those studies reporting clinical assessment of breast cosmesis did
not report a difference at five years (Whelan 2002), median follow
up of 8.1 years (Owen 2006) (RR 1.17; 95% CI 0.98 to 1.39, P =
0.09) and 12 years (Whelan 2002). No difference was reported for
clinical assessment of change in breast appearance (Owen 2006).
Photographic assessment of change in breast appearance (assessed
at amix of both two andfive years followup) reportednodifference
for the comparison of 41.6 Gy with 50 Gy: HR 1.09 (95% CI
0.85 to 1.40, P = 0.62) (START A 2008) and for 40 Gy with 50
Gy: HR 0.83 (95% CI 0.66 to 1.04, P = 0.06) (START B 2008).
The comparison of 39 Gy with 50 Gy: HR 0.69 (95% CI 0.52
to 0.91, P = 0.01) (START A 2008) appeared to be associated
with less photographic change in breast appearance for the shorter
fractionation arm.
For overall survival, there was no significant difference between
the techniques: RR 0.89 (95%CI 0.77 to 1.04, P = 0.16) (Analysis
1.6). The use of unconventional fractionation was associated with
significantly decreased acute radiation skin toxicity: RR 0.21 (95%
CI 0.07 to 0.64, P = 0.007) (Analysis 1.8). There was no sig-
nificant difference between the techniques for late skin toxicity,
late subcutaneous toxicity, ischaemic heart disease or rib fractures.
No data were available for costs, quality of life or women’s prefer-
ence. There are limitations related to assessment of subjective out-
comes, such as cosmesis and breast induration, but this was well-
performed using standardised tools by trained observers in both
trials (Owen 2006; Whelan 2002), with blinding of the outcome
assessors to the treatment allocation in Owen 2006, START A
2008, START B 2008 and Whelan 2002.
The findings of this review provide reassurance that the practice
of offering shortened radiation fractionation regimens to carefully
selected groups of patients is unlikely to be detrimental in terms
of local control, breast appearance, survival or late radiation breast
toxicity. However, there are some caveats.
(1) These results are mostly applicable to women with small to
medium breasts, aged greater than 50 years, with node negative
tumours less than 3 cm in size, with negative pathological margins.
The women in Owen 2006, START A 2008 and START B 2008
had a mean age of 54.5 to 57.4 years and approximately 75% of
women in Whelan 2002 were aged over 50 years.
A total of 5603 (79%) of the women enrolled in the four trials were
node negative (see additional Table 6) and they all had negative
pathological margins. Whelan 2002 limited the eligible women
to those with a cup size separation of 25 cm or less because, for
women with larger breasts, there is concern that altered fractiona-
tion may cause more toxicity. In START A 2008, START B 2008
and Owen 2006 82% (3067/3696) of women had small/medium
breasts (from photographs taken at baseline). For the women in
the analysis where the breast size is known (i.e. breast separation
or from photos taken at baseline), 4301/4930 (87%) had small
or medium breasts (see Characteristics of included studies). This
represents 60% of the total number of women included in the
analysis. The vast majority (6369/7095, 89.8%) of women had
tumours less than 3 cm. Although women with T3 tumours (size
greater than 5 cm) were eligible for the Owen 2006, START A
2008 and STARTB2008 studies, they comprised 1.6% (22/1410)
of the study population and only 0.33% of the women analysed
in the review.
(2) The follow up (five years, with 10-year data for two trials)
is not adequate to detect differences in breast cancer mortality.
If, however, there are truly no differences in local recurrence or
late toxicity (e.g. cardiac morbidity) one would not expect to see
differences in mortality. Late effects of radiation therapy, e.g. skin
toxicity and subcutaneous induration (which may be detrimental
to cosmesis) increase with time. This increase in both skin toxicity
and subcutaneous toxicity was reported by Whelan 2002, who
showed that late skin toxicity doubled (6% versus 3%) and late
subcutaneous toxicity (8% versus 4%) was increased with longer
follow up. Follow up in the studies for cosmetic outcomes varied
in length. For Owen 2006, 63% have 5-year follow up and 11%
have 10-year follow up for late change in breast appearance. For
START A 2008 and START B 2008 it is not specified how many
of the women photographically assessed for late change in breast
appearance were followed for five years. All women assessed in
Whelan2002 had five years of followup.With longer followup for
the remainder of the cohorts, we may see increased late radiation
toxicity with potential detriment to cosmesis.
In total, 271 local recurrences at five years were reported in 7095
women. The Owen 2006 study was not powered to detect sig-
nificant differences in local recurrence. Using an alpha/beta ratio
of 4 for breast tumour cells (Fowler 1989; Steel 1987; Williams
1985) allows conversion of radiation doses to a common biologi-
cal equivalent dose (BED) (Fowler 1989; Steel 1997). When the
altered fractionation regime radiation doses are converted to BED
(see Table 7), it is clear that the unconventional regimens (39Gy in
13 fractions, 42.5 Gy in 13 fractions, 41.6 Gy in 13 fractions and
40 Gy in 15 fractions) (Owen 2006; START A 2008; START B
2008; Whelan 2002) have lower biological equivalent doses than
the conventional 50 Gy in 25 fractions. Bartelink 2008 showed
that all women irrespective of age showed improved local control
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with addition of a 16 Gy boost to conventionally fractionated ra-
diotherapy. The reason for the lack of a difference in local control
with lower BED used in the altered fractionation trials is uncer-
tain. Possible reasons include inadequate follow up so far or the
impact of the boost used in 47% of women treated (see Table
4). For START A 2008 and START B 2008, the use of a boost
was roughly equally divided between the treatment arms. While
boosts are associated with decreased local recurrence, they are also
associated with poorer cosmesis (Bartelink 2007).
It has not been possible at this time to answer questions of cost,
quality of life and patient preferences within this review. There
was significantly less acute radiation toxicity in the unconventional
arm and one could reasonably expect that shorter regimens are
more readily tolerated and, therefore, would enhance quality of
life for women.
A detailed assessment of quality of life is planned for a subset of
patients enrolled in START A 2008 and START B 2008, which
may providemore information. Little is known about patient pref-
erences in this setting but as rural women have consistently been
shown to have more mastectomies in comparison with women
who live in bigger centres (Nattinger 2001; Schroen 2005) it may
be that they choose mastectomy to reduce their time away from
home (assuming they are offered conservative treatment as fre-
quently as women in urban areas). Another trial has been identi-
fied (Wallace 1993) and we have contacted the authors requesting
further information.
(3) We do not have information about combining other therapies
(for example, trastuzumab) with these fractionation regimens, al-
though observational data suggest it to be a safe practice with con-
ventionally fractionated radiation therapy (Romond 2005).
(4) The optimum ’dose’ of altered fractionation remains unknown.
In Owen 2006 and START A 2008, two novel altered fraction-
ation schedules were tested, however we were not able to analyse
them separately to see if one was superior to the other. In addi-
tion, new techniques, such as accelerated partial breast irradiation,
shorten treatment time even more by using larger fraction sizes to
a smaller volume of breast tissue. These techniques are the subject
of a number of ongoing trials.
(5) New technology, for example, intensity modulated radiation
therapy (IMRT), which uses multiple radiation beams in order to
make treatment highly conformal (thus reducing dose to normal
structures) and improve dose distribution has been shown to de-
crease acute radiotherapy toxicity (Donovan 2007) and improve
cosmesis (Pignol 2008).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In selectedwomenwith early breast cancer (node negative tumours
with negative margins and size 3 cm or less) shortened fractiona-
tion regimensmay be considered if the breast is of small tomedium
size. Longer follow up is required to obtain a full assessment of the
impact of altered fractionation on local recurrence rates, cosmesis
and other toxicity.
Implications for research
There are a number of questions still unanswered that relate to the
use of altered fraction size in the treatment of early breast cancer
for women undergoing breast cancer surgery.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Owen 2006
Methods Randomised, multi-centre setting: tertiary cancer centres
Participants 1410 British women with operable (T1-3N0-1MO) invasive breast cancer requiring
radiotherapy. 1138 women had small or medium breasts (from photographs at baseline)
. Median follow up 9.7 years (range 7.8 to 11.8). Mean age of women: 54.5 years
Interventions Experimental arm (n = 474): 39 Gy in 13 fractions, or 42.9 Gy in 13 fractions (n = 466)
over 5 weeks
Control arm (n = 470): 50 Gy in 25 fractions over 5 weeks
Outcomes Primary outcome: late change in breast appearance (scored from photos). Secondary
endpoints: palpable breast induration and ipsilateral breast recurrence.Women reviewed
3-monthly to 36 months, 6-monthly to 60 months, then annually. Annual physician
toxicity review. Photographs annually to 60 months, then at 10 years in all evaluable
patients
Notes Photos: frontal photos taken after surgery before RT, then annually to 5 years and at 10
years under standard conditions. Photos scored by 3 observers
Low risk of bias
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Quote: “were randomised” (Abstract).Not
adequately described to be sure it was truly
randomised
Allocation concealment? Low risk Quote: “randomisation achieved by a tele-
phone call to the Clinical trials and Statis-
tics Unit at the Institute of Cancer Re-
search, Sutton” (Para 3, page 10)
Quote: “Randomisation was done by tele-
phone at the Clinical trials and Statistics
Unit (ICR-CTSU) at the Institute of Can-
cer Research, Sutton by the clinician (early
in the trial), who recorded it in the patient’s
notes and did not have any further role
in the randomisation process, and then by
a research nurse. Although randomisation
was not blinded...” (Para 2, page 3)
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Owen 2006 (Continued)
Blinding?
Subjective outcomes
Low risk Patient: not mentioned, unlikely to be a
problem for Nurse or Clinician assessed
outcomes
Personnel: not mentioned, probably not
done
Assessors: photographic assessors blinded
to treatment arm. Quote: “Assessments
of the change in breast appearance were
blinded” (Para 3, page 2). Clinical assess-
ments were not blinded (although done by
many people, whichmay potentially reduce
bias)
Blinding?
Objective outcomes
Unclear risk Patient: not mentioned, probably not
done, unlikely to be a source of bias
Personnel: not mentioned, probably not
done
Assessors: not mentioned, probably not
done.
Although time points for clinical examina-
tions were pre-specified, there is no men-
tion of the timing of mammograms
Incomplete outcome data addressed?
Subjective outcomes
High risk Cosmetic outcome, late radiation toxicity
and quality of life:1202/1410 women had
photos at both baseline and at a later time
point. Quote: “reasons for non-availabil-
ity explored, and no evidence was observed
that this was associated with either the frac-
tionation schedule or to the probability of
experiencing future normal tissue event or
local relapse.” (These data not reported).
Reasons for attrition not detailed, a poten-
tial source of bias
The first 806/1410 women had prospec-
tively collected physician assessments (in-
cluding normal tissue effects) for ten years.
It is not clear why these women were cho-
sen and the others excluded from the sam-
ple
Incomplete outcome data addressed?
Objective outcomes
Low risk Attrition: 42.9 Gy in 13 fractions; 8 lost to
follow up, 4 moved, 4 unable to attend
39 Gy in 13 fractions; 2 lost to follow up,
1 emigrated, 1 unable to be traced
50 Gy in 25 fractions; 8 lost to follow up,
7 moved (2 emigrated), 1 did not attend
appointments and was then discharged
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Owen 2006 (Continued)
Free of selective reporting? Unclear risk Outcomes specified in methods/protocol:
late change in breast appearance (scored
fromphotographs), palpable breast indura-
tion (fibrosis), ipsilateral tumour recur-
rence
Outcomes reported in paper: late change
in breast appearance (scored from pho-
tographs), clinical assessment of cosme-
sis, breast shrinkage, distortion, oedema,
induration, telangiectasia, arm oedema,
shoulder stiffness, local recurrence, distant
relapse, contralateral breast cancer
Free of other bias? High risk Premature reporting for primary endpoint
(subjective). Quote: “minimum 5 year
follow up”. Study stopped early because
START trials commenced
START A 2008
Methods Randomised, multi-centre setting: tertiary cancer centres
Participants 2236 British women with operable (T1-3N0-1M0) invasive breast cancer requiring
radiotherapy. 1071/1250 women (with photographs available at baseline) had small or
medium breasts. Median follow up 5.1 years (range 4.4 to 6.0). Mean age 57.2 years
Interventions Experimental arm (n = 750): 41.6 Gy in 13 fractions or 39 Gy in 13 fractions (n = 737)
over 5 weeks
Control arm (n = 749): 50 Gy in 25 fractions over 5 weeks
Outcomes Primary outcome: loco-regional relapse, normal tissue effects and quality of life.
Secondary outcomes: disease-free survival, overall survival, second primaries, health eco-
nomics consequences (not specified) and toxicity. Women reviewed annually for loco-
regional relapse and normal tissue effects
Notes Normal tissue effects assessed by photos, patient and doctor assessments. Photos at
baseline, 2 and 5 years (blinded assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “randomly assigned” (Abstract)
. Quote: “computer generated and not
blinded” (Abstract). Quote: “START A pa-
tients were randomised” (Para 3, page 3).
Probably done
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START A 2008 (Continued)
Allocation concealment? Low risk Quote: “Randomisation was arranged via
telephone at the Clinical Trials and Statis-
tics Unit at the Institute of Cancer Re-
search (ICR-CTSU), Sutton, UK, where
the patient details were recorded and treat-
ment allocated. Randomisation was not
blinded. Computer-generated permuted
blocks were used as a method of allocation”
(Para 4, page 3)
Provided those undertaking recruitment
are not aware that permuted blocks are be-
ing used, or the block size, then this should
not distort the recruitment
Blinding?
Subjective outcomes
Low risk Patient: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: Quote: “Changes in breast ap-
pearance (photographic) were scored by
three observers blinded to patient identity,
treatment allocation and year of follow up”
(Para 3, page 4). Probably done and this is
most important for assessment of this sub-
jective primary outcome
Blinding?
Objective outcomes
Unclear risk Patient: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: not mentioned, probably not
done. Although time points for clinical ex-
aminations were pre-specified, there is no
mention of the timing of mammograms,
which may be a source of bias
Incomplete outcome data addressed?
Subjective outcomes
Unclear risk Cosmetic outcome, late radiation toxicity
and quality of life: Quote: “1129/2236 en-
rolled in quality of life study”
It is not clear how the patients enrolled in
the quality of life study were selected
1306/2236 enrolled in photographic
study: assessed in 1055 patients with both
a baseline and a follow-up photograph
Quote: “There were no associations be-
tween score for change in breast appearance
(photographic) at two years or patient de-
mographic or treatment characteristics and
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START A 2008 (Continued)
whether or not the patient had a five-year
assessment (data not shown).”
It is not clear why not all patients were en-
rolled in the photographic study
Incomplete outcome data addressed?
Objective outcomes
Low risk Attrition described clearly: Quote: “41.6
Gy in 13 fractions; 2 with baseline data
only, 1 moved, 1 unknown, 39 Gy in 13
fractions; 2 with baseline data only, 2 with-
drew consent to follow up after randomisa-
tion, 50 Gy in 25 fractions; 5 with baseline
data only, 3 withdrew consent to follow up
after randomisation, 2 moved”
Free of selective reporting? Unclear risk Outcomes specified in methods/protocol:
local-regional tumour relapse, late nor-
mal tissue effects (photographic change in
breast appearance). Quality of life, dis-
ease-free survival, overall survival, second
primary cancers, health economic conse-
quences, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung fi-
brosis, brachial plexopathy
Outcomes reported in paper: local-regional
tumour relapse, distant relapse,disease-free
survival, overall survival, second primary
cancers, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung
fibrosis, brachial plexopathy, disease-free
survival, overall survival, second primary
cancers, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung fi-
brosis, brachial plexopathy
“Quality of life outcomeswill be the subject
of another paper”. Health economic con-
sequences not reported
Free of other bias? High risk Quote:“Not all patients had photographs
available at both 2 and 5 years, for reasons
including the 5-year assessment not being
yet due at the time of scoring and analysis.
..” This may represent early reporting
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START B 2008
Methods Randomised, multi-centre setting: tertiary cancer centres
Participants 2215 British women with operable (T1-3N0-1M0) invasive breast cancer requiring
radiotherapy. 858/1036women treatedwith breast conserving surgery (with photographs
available at baseline) had small or medium sized breasts. Median follow up 6.0 years
(range 5.0 to 6.2). Mean age 57.4 years
Interventions Experimental arm (n = 1110): 40 Gy in 15 fractions over 3 weeks
Control arm (n = 1105): 50 Gy in 25 fractions over 5 weeks
Outcomes Primary outcome: loco-regional relapse, normal tissue effects and quality of life. Sec-
ondary outcomes: disease-free survival, overall survival, second primaries, health eco-
nomics consequences (not specified) and toxicity. Women reviewed annually for loco-
regional relapse and normal tissue effects
Notes Normal tissue effects assessed by photos, patient and doctor assessments. Photos at
baseline, 2 and 5 years (blinded assessment)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “randomly assigned” (Abstract)
. Quote: “computer generated and not
blinded” (Abstract). Quote: “START B pa-
tients were randomised” (Para 2, page 2).
Probably done
Allocation concealment? Low risk Quote: “Randomisation was arranged via
telephone at the Clinical Trials and Statis-
tics Unit at the Institute of Cancer Re-
search (ICR-CTSU), Sutton, UK, where
the patient details were recorded and treat-
ment allocated. Randomisation was not
blinded. Computer-generated permuted
blocks were used as a method of allocation”
(Para 2, page 2)
Provided those undertaking recruitment
are not aware that permuted blocks are be-
ing used, or the block size, then this should
not distort the recruitment
Blinding?
Subjective outcomes
Low risk Patient: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: Quote: “Changes in breast ap-
pearance (photographic) were scored by
three observers blinded to patient identity,
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START B 2008 (Continued)
treatment allocation and year of follow up”
(Para 2, page 3). Probably done and this is
most important for assessment of this sub-
jective primary outcome
Blinding?
Objective outcomes
Unclear risk Patient: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: not mentioned, probably not
done. Although time points for clinical ex-
aminations were pre-specified, there is no
mention of the timing of mammograms,
which may be a source of bias
Incomplete outcome data addressed?
Subjective outcomes
Low risk Attrition: 40 Gy in 15 fractions arm; 10
with baseline data only, 3 ineligible, 7 with-
drew consent to follow up after randomi-
sation
50 Gy in 25 fractions; 9 with baseline data
only, 5 withdrew consent to follow up after
randomisation, 2 moved, 2 unknown (Fig
1)
Unlikely to introduce bias in objective out-
comes
Incomplete outcome data addressed?
Objective outcomes
Unclear risk Cosmetic outcome, late radiation toxicity,
quality of life.
1094/2215 enrolled in photographic study
Quote: “There were no associations be-
tween score for change in breast appearance
(photographic) at two years or patient de-
mographic or treatment characteristics and
whether or not the patient had a five-year
assessment (data not shown).”
It is not clear why not all patients were en-
rolled in photographic study
1079/2215 enrolled in quality of life study
It is not clear how the patients enrolled in
the quality of life study were selected
Free of selective reporting? Unclear risk Outcomes specified in methods/protocol:
local-regional tumour relapse, late nor-
mal tissue effects (breast, arm and shoul-
der) assessed by photographic, self-reported
and doctor assessed. Quality of life, dis-
ease-free survival, overall survival, second
primary cancers, health economic conse-
quences, ischaemic heart disease, symp-
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START B 2008 (Continued)
tomatic rib fracture, symptomatic lung fi-
brosis, brachial plexopathy
Outcomes reported in paper: local-regional
tumour relapse, distant relapse, disease-
free survival, overall survival, change in
breast appearance (photographic), patient
self-assessment of breast ischaemic heart
disease, symptomatic rib fracture, symp-
tomatic lung fibrosis, brachial plexopa-
thy, acute radiation therapy reactions, con-
tralateral breast cancers, second primary
cancers. Health economic consequences
have not been reported
Free of other bias? High risk Version of “early stopping” or early report-
ing, (median follow up 6.0 years). 1094 en-
rolled in photographic study, but the out-
come assessed in 923 women (with both
photograph at baseline and either 2 or 5
years follow up)
It is possible that the numbers of women
with 5 years follow up is small, but detail is
not given
Whelan 2002
Methods Randomised, multi-centred, setting: tertiary institutions
Participants 1234 Canadian women with invasive breast cancer (< 5 cm, i.e. no T3/T4 lesions,
negative margins and node negative) treated with lumpectomy. Exclusions: those with
multi-centric disease, large breasts (separation > 25 cm) and those with bilateral breast
cancer. Median follow up 12 years. Approximately 75% of the women were aged over
50 years
Interventions Experimental arm (n = 622): radiation dose to breast alone; 42.5 Gy in 16 fractions
(dose per fraction 2.65 Gy, BED = 70.65)
Control arm (n = 612): radiation dose 50 Gy in 25 fractions (dose per fraction 2.0 Gy,
BED = 75)
Outcomes Primary outcome: local recurrence of invasive breast cancer in treated breast
Secondary outcomes: distant recurrence of invasive breast cancer, death, breast cosmesis
and late radiation toxicity. Cosmesis assessed using EORTC Cosmetic Rating System
(by trained nurse). Global cosmetic outcome assessed using 4-point scale.
Late radiation toxicity assessed by trained nurse using RTOG/EORTC late radiation
morbidity scale
Notes Concurrent interventions were evenly divided between the 2 arms: 254 women in the
experimental arm received tamoxifen and 251 in the control arm, 66 women in the
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Whelan 2002 (Continued)
experimental arm received chemotherapy and 66 in the control arm. Moderate risk of
bias
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “randomly assigned” (Abstract)
Quote: “computer-generated central ran-
domisation schedule within strata defined
by age (< 50 years or ≥ 50 years), tumour
size (≤ 2 cm or > 2 cm), adjuvant systemic
therapy (tamoxifen, any chemotherapy or
on therapy) and centre” (Para 3, page 4)
It sounds as if it was truly randomised
Allocation concealment? Unclear risk Quote: “computer-generated central ran-
domisation schedule within strata defined
by age (< 50 years or ≥ 50 years), tumour
size (≤ 2 cm or > 2 cm), adjuvant systemic
therapy (tamoxifen, any chemotherapy or
on therapy) and centre” (Para 3, page 4)
It is not explicitly stated that the randomi-
sation process was concealed, although it
was central
Blinding?
Subjective outcomes
Low risk Patient: not mentioned, but the patient
cannot have been blinded, as they would
know how many fractions of RT they re-
ceived. This may affect how they report the
subjective outcomes, although they were
not patient assessed
Personnel: not mentioned, probably not
done
Assessors: Not mentioned (unlikely, given
the lack of blinding in other personnel) but
unlikely to introduce bias
Blinding?
Objective outcomes
Low risk Patient: not mentioned, but the patient
cannot have been blinded, as they would
know how many fractions of RT they
received. Not possible to blind patient,
but unlikely to introduce bias in objective
outcomes, especially as interval for mam-
mography pre-specified. Quote: “mammo-
grams six monthly, then annually”
Personnel: not mentioned, probably not
done
Assessors: no commentmade, but as regular
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Whelan 2002 (Continued)
mammograms performed, a lack of blind-
ing in outcome assessors could contribute
to lead time bias in the diagnosis of local
recurrence, but this would be unlikely to
be significant over a prolonged follow-up
period
Incomplete outcome data addressed?
Subjective outcomes
High risk Cosmetic outcome was assessed in 735/
1220 women; those who had follow up to
5 years at the time of the initial trial re-
port. It may be that the reason others did
not have five years follow up is because they
had not been in the trial long enough, but
it could also potentially be due to other
reasons, perhaps because of withdrawal or
non-attendance
Late radiation toxicity was assessed in 752/
1220 women at 5 years. It may be that not
all women had 5 years follow up, but this
is not made clear. The authors make the
point that most of the toxic effects of RT
are evident by 5 years follow up
Incomplete outcome data addressed?
Objective outcomes
Unclear risk Exclusions: 0
Although the number analysed equals the
number randomised, it seems unlikely that
all the patientswould be available for follow
up after a period of as long as 10 years. If
there are missing data, there is no informa-
tion given about how they were dealt with
Free of selective reporting? Unclear risk Outcomes specified in methods/protocol:
Any local recurrence in treated breast, dis-
tant recurrence, death, breast cosmesis, late
RT toxicity. Cosmetic outcome: at 3 and 5
years. Late RT toxicity: at 3 and 5 years
Outcomes reported in paper: local recur-
rence-free survival, local recurrence rate,
disease-free survival, death, breast cosmesis,
late RT toxicity (both at 3 and 5 years), skin
toxicity, subcutaneous toxicity, rib fractures
and pneumonitis
Free of other bias? High risk Early reporting, not all women had 5 years
follow up at the time of the report. The
details in the second report are too sketchy
to make further comment (abstract only)
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Gy: Gray
RT: radiotherapy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Angelakis 1973 Not a RCT
Anon 1981 Surgery was wide local excision versus mastectomy
Anon 1982 Not a RCT
Anon 1999 Not a RCT
Ash 1995 Not a RCT
Asrari 1999 Not a RCT
Baglan 2001 Did not examine external beam radiation
Baillet 1990 Did not examine 2 Gy versus > 2 Gy per fraction
Bartelink 1998 Not a RCT
Bates 1975 Surgery was modified radical mastectomy
Bates 1988 Surgery was modified radical mastectomy
Bedwinik 1990 Not a RCT
Brinkley 1984 Surgery was modified radical mastectomy
Bruce 1971 Surgery was modified radical mastectomy versus simple mastectomy
Di Biase 2002 Not a RCT
Dvivedi 1978 Surgery was modified radical mastectomy and regional radiation therapy was examined
EBCTG 2000 Not a RCT
Fentiman 1991 Not a RCT
Formenti 2002 Partial breast radiation therapy was examined
Goel 2002 Surgery was modified radical mastectomy
Gorodetsky 1999 Not a RCT
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Kovarik 1995 Not a RCT
Liljegren 1993 Intervention was radiation therapy in experimental arm only
Mladenovic 2001 Not a RCT
Moody 1994 Refers to women randomised in Owen 2006, but only patients randomised from 1986 to 1991
Moonen 1994 Not a RCT
Nyman 1994 Not a RCT
Nyman 1995 Not a RCT
Olivotto 1996 Intervention was +/- aspirin
Ortholan 2003 Not a RCT
Poortmans 2001 Not a RCT
Ptaszynski 1999 Examined boost versus no boost
Rodger 1998 Not a RCT
Romestaing 1997 Examined boost versus no boost
Sanguineti 2001 Was a chemotherapy trial
Shelley 2000 Not a RCT
Svoboda 1992 Not a RCT
Turesson 1984 Not a RCT
UK-FAST 2009 Control arm not conventional radiotherapy
van Tienhoven 1991 Not a RCT
Veronesi 2001 Not a RCT
Vicini 1997 Not a RCT
Vicini 2001 Not a RCT
Vrieling 2000 Examined boost versus no boost
Wallgren 1978 Investigates preoperative radiation therapy
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Wazer 2002 Not a RCT
Yamada 1999 Not a RCT
Yarnold 1991 Not a RCT
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Whelan 2010
Methods Randomised controlled trial
Participants Sample size: 1234
Inclusion criteria: women with histological diagnosis of invasive carcinoma of the breast and no evidence of metastatic
disease, has had a lumpectomy (including segmental resection and partial mastectomy), patient has not had an axillary
dissection or for patients who have had an axillary dissection, all nodes are negative for metastatic disease
Interventions Arm 1 (control group): standard whole-breast irradiation at a dose of 50 Gy in 25 fractions over a period of 35 days
Arm 2 (intervention group): acceleration, hypofractionated whole-breast irradiation at a dose of 42.5 Gy given in 16
fractions over a period of 22 days
Radiation was delivered by means of two opposed tangential fields with treatment provided daily from Monday
through Friday
Outcomes Primary outcome: local breast recurrence
Secondary outcome: distant (including regional) recurrence of breast cancer, second cancers including contralateral
breast cancer, breast cosmesis, late toxic effects of radiation and death
Notes
Characteristics of ongoing studies [ordered by study ID]
ISRCTN12852634
Trial name or title Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy following breast
conservation surgery for early breast cancer (IMPORT LOW)
Methods Randomised controlled trial
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ISRCTN12852634 (Continued)
Participants -Age 50 years
-Primary breast conservation surgery +/- adjuvant systemic therapy
-Pathological tumour size less than or equal to 2.0 cm pT1a-c
-Invasive adenocarcinoma
-Unifocal disease (Grade 1 or II)
-Minimum microscopic margin of non-cancerous tissue greater than or equal to 2 mm
-No lymph-vascular invasion
-Axillar lymph nodes negative
-No blood borne metastases
Interventions Arm 1: Control group - current standard radiotherapy to the whole breast
Arm 2: Test arm 1 - reduced radiotherapy to the whole breast with standard radiotherapy to the partial breast
Arm 3: Test arm 2 - standard radiotherapy to the partial breast only
Outcomes Local tumour control in the ipsilateral breast
Location of tumour relapse
Contralateral primary tumours
Regional and distant metastases
Late adverse effects in normal tissues
Quality of life
Economic evaluation
Starting date March 2007
Contact information Professor John Yarnold (http://www.cancerhelp.org.uk/help/default.asp?page=18871#low)
Notes Anticipated end date: October 2019
NCT00909818
Trial name or title Hypofractionated versus standard fractionated whole breast irradiation to node-negative breast cancer
Methods Randomised controlled trial
Parallel assignment
Participants -Women 41 years old
-Operated with breast concerning strategy for (i) invasive breast cancer, pT1-2, pN0-1 mi, M0 OR (ii)
carcinoma in situ of the breast, Tissue 20 mm and/or van Nuys > 1 and/or margin <10 mm
Interventions Arm 1: Stardard fractionated radiotherapy (active comparator)
-50 Gy / 25 fractions, 2 Gy / fraction, 5 fractions per week
Arm 2 : Hypofractionated radiotherapy (experimental)
-Hypofractionated radiotherapy 40 Gy / 15 fractions
Outcomes Grade 2 or 3 fibrosis 3 years after radiotherapy
Any other late morbidity after adjuvant radiotherapy
Genetic risk profile for late morbidity
Recurrent/Survival
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NCT00909818 (Continued)
Starting date May 2009
Contact information Birgitte Offersen (bvo@oncology.dk)
Notes Anticipated end date: May 2022
Wallace 1993
Trial name or title WMOA (West Midlands Oncology Association Trial)
Methods -
Participants Women attending Queen Elizabeth Hospital Birmingham for postoperative radiation following lumpectomy
for carcinoma of the breast
Interventions Experimental (n = 31): 40 Gy in 15 fractions plus boost 10-14 MeV of 15 Gy in 5 fractions
Conventional (n = 32): 50 Gy in 25 fractions plus boost as above
Outcomes -
Starting date -
Contact information -
Notes This represents a cohort of a larger trial - more details have been requested
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D A T A A N D A N A L Y S E S
Comparison 1. Unconventional fractionation versus conventional fractionation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Local recurrence at 5 years (raw
data from authors)
4 7095 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.73, 1.19]
2 Local recurrence at 5 years data
from paper
4 7095 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.76, 1.22]
3 Local recurrence at 5 years 2 3449 Hazard Ratio (95% CI) 0.93 [0.63, 1.38]
4 Local recurrence at 10 years 2 2644 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.77, 1.29]
5 Cosmesis 1 806 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.98, 1.39]
6 Deaths at 5 years 3 5685 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.77, 1.04]
7 Deaths at 5 years 2 3449 Hazard Ratio (95% CI) 0.81 [0.65, 1.00]
8 Acute skin toxicity 2 4451 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.07, 0.64]
9 Late skin toxicity 1 752 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.44, 2.22]
10 Late subcutaneous toxicity 2 1558 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.81, 1.24]
11 Ischaemic heart disease (left
sided tumours)
2 4451 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.32, 3.56]
12 Rib fractures at 5 years 3 5685 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.25, 3.41]
Analysis 1.1. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 1
Local recurrence at 5 years (raw data from authors).
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 1 Local recurrence at 5 years (raw data from authors)
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 71/940 35/470 36.1 % 1.01 [ 0.69, 1.50 ]
START A 2008 52/1487 22/749 22.7 % 1.19 [ 0.73, 1.94 ]
START B 2008 20/1110 33/1105 25.6 % 0.60 [ 0.35, 1.04 ]
Whelan 2002 18/622 20/612 15.6 % 0.89 [ 0.47, 1.66 ]
Total (95% CI) 4159 2936 100.0 % 0.93 [ 0.73, 1.19 ]
Total events: 161 (Hypofractionation), 110 (Conventional)
Heterogeneity: Chi2 = 3.57, df = 3 (P = 0.31); I2 =16%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.2. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 2
Local recurrence at 5 years data from paper.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 2 Local recurrence at 5 years data from paper
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 71/940 35/470 34.8 % 1.01 [ 0.69, 1.50 ]
START A 2008 59/1487 25/749 24.8 % 1.19 [ 0.75, 1.88 ]
START B 2008 25/1110 34/1105 25.4 % 0.73 [ 0.44, 1.22 ]
Whelan 2002 18/622 20/612 15.0 % 0.89 [ 0.47, 1.66 ]
Total (95% CI) 4159 2936 100.0 % 0.97 [ 0.76, 1.22 ]
Total events: 173 (Hypofractionation), 114 (Conventional)
Heterogeneity: Chi2 = 2.06, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.3. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 3
Local recurrence at 5 years.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 3 Local recurrence at 5 years
Study or subgroup Hypofractionation Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
START B 2008 0/1110 0/1105 58.1 % 0.72 [ 0.43, 1.21 ]
Whelan 2002 0/622 0/612 41.9 % 1.33 [ 0.72, 2.44 ]
Total (95% CI) 100.0 % 0.93 [ 0.63, 1.38 ]
Heterogeneity: Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.4. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 4
Local recurrence at 10 years.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 4 Local recurrence at 10 years
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 99/940 48/470 60.8 % 1.03 [ 0.74, 1.43 ]
Whelan 2002 39/622 41/612 39.2 % 0.94 [ 0.61, 1.43 ]
Total (95% CI) 1562 1082 100.0 % 0.99 [ 0.77, 1.29 ]
Total events: 138 (Hypofractionation), 89 (Conventional)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.5. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 5
Cosmesis.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 5 Cosmesis
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 244/535 106/271 100.0 % 1.17 [ 0.98, 1.39 ]
Total (95% CI) 535 271 100.0 % 1.17 [ 0.98, 1.39 ]
Total events: 244 (Unconventional), 106 (Conventional)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 6
Deaths at 5 years.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 6 Deaths at 5 years
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 172/1487 84/749 37.1 % 1.03 [ 0.81, 1.32 ]
START B 2008 107/1110 138/1105 45.9 % 0.77 [ 0.61, 0.98 ]
Whelan 2002 48/622 51/612 17.1 % 0.93 [ 0.63, 1.35 ]
Total (95% CI) 3219 2466 100.0 % 0.89 [ 0.77, 1.04 ]
Total events: 327 (Unconventional), 273 (Conventional)
Heterogeneity: Chi2 = 2.79, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 1.7. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 7
Deaths at 5 years.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 7 Deaths at 5 years
Study or subgroup Unconventional Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
START B 2008 0/1110 0/1105 70.9 % 0.76 [ 0.59, 0.98 ]
Whelan 2002 0/622 0/612 29.1 % 0.95 [ 0.64, 1.40 ]
Total (95% CI) 100.0 % 0.81 [ 0.65, 1.00 ]
Heterogeneity: Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.94 (P = 0.052)
Test for subgroup differences: Not applicable
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Favours experimental Favours control
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Analysis 1.8. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 8
Acute skin toxicity.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 8 Acute skin toxicity
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 0/1487 2/749 20.4 % 0.10 [ 0.00, 2.10 ]
START B 2008 3/1105 13/1110 79.6 % 0.23 [ 0.07, 0.81 ]
Total (95% CI) 2592 1859 100.0 % 0.21 [ 0.07, 0.64 ]
Total events: 3 (Unconventional), 15 (Conventional)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0067)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 9
Late skin toxicity.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 9 Late skin toxicity
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Whelan 2002 12/394 11/358 100.0 % 0.99 [ 0.44, 2.22 ]
Total (95% CI) 394 358 100.0 % 0.99 [ 0.44, 2.22 ]
Total events: 12 (Unconventional), 11 (Conventional)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 10
Late subcutaneous toxicity.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 10 Late subcutaneous toxicity
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006 163/535 77/271 79.6 % 1.07 [ 0.85, 1.35 ]
Whelan 2002 20/394 25/358 20.4 % 0.73 [ 0.41, 1.29 ]
Total (95% CI) 929 629 100.0 % 1.00 [ 0.81, 1.24 ]
Total events: 183 (Hypofractionation), 102 (Conventional)
Heterogeneity: Chi2 = 1.56, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 11
Ischaemic heart disease (left sided tumours).
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 11 Ischaemic heart disease (left sided tumours)
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 4/1487 1/749 25.0 % 2.01 [ 0.23, 17.99 ]
START B 2008 3/1105 4/1110 75.0 % 0.75 [ 0.17, 3.36 ]
Total (95% CI) 2592 1859 100.0 % 1.07 [ 0.32, 3.56 ]
Total events: 7 (Unconventional), 5 (Conventional)
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Unconventional fractionation versus conventional fractionation, Outcome 12
Rib fractures at 5 years.
Review: Fraction size in radiation treatment for breast conservation in early breast cancer
Comparison: 1 Unconventional fractionation versus conventional fractionation
Outcome: 12 Rib fractures at 5 years
Study or subgroup Unconventional Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 3/1487 1/749 27.5 % 1.51 [ 0.16, 14.50 ]
START B 2008 2/1105 2/1110 41.2 % 1.00 [ 0.14, 7.12 ]
Whelan 2002 0/622 1/612 31.3 % 0.33 [ 0.01, 8.04 ]
Total (95% CI) 3214 2471 100.0 % 0.93 [ 0.25, 3.41 ]
Total events: 5 (Unconventional), 4 (Conventional)
Heterogeneity: Chi2 = 0.59, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.92)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
A D D I T I O N A L T A B L E S
Table 1. EORTC Cosmetic Rating System
Global cosmetic
0 no difference or excellent
1 small difference or good
2 moderate difference or fair
3 large difference or poor
Table 2. RTOG/EORTC late radiation morbidity scale
Score Definition
0 No toxicity
1 Slight toxicity
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Table 2. RTOG/EORTC late radiation morbidity scale (Continued)
2 Moderate toxicity
3 Marked toxicity
4 Severe toxicity
Table 3. Induration of treated breast (four-point scale used in Owen 2006)
Score Definition
0 None
1 Mild
2 Moderate
3 Marked
Table 4. Boost for women treated with breast conservation
STUDY Breast conservation Boost experimental arm Boost control arm Total
START A 2008 1900 771/1269 (61%) 381/631 (60%) 1152/1900 (61%)
START B 2008 2038 446/1018 (44%) 422/1020
(41%)
868/2038
(43%)
Owen 2006 1410 - - 1051/1410 (75%)
Whelan 2002 1234 0/622 0/612 0/1234 (0%)
3071/6582 (47%)
Table 5. Four-point scale used to report breast cosmesis in Owen 2006
Breast Cosmesis
Excellent
Good
Fair
Poor
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Table 6. Node negative women
Study Node negative women
Whelan 2002 1234
Owen 2006 1187
START A 2008 1547
START B 2008 1635
Total 5603
Table 7. Conversion of altered fractionation regimen to BED
Dose Fractions BED equivalent
50 Gy 25 75
39 Gy 13 68.25
42.5 Gy 16 70.2
41.6 Gy 13 74.9
40 Gy 15 66.6
A P P E N D I C E S
Appendix 1. Search strategy - MEDLINE (Ovid) 1966 to 4 August 2009
1 breast neoplasms/
2 (breast cancer or breast adenocarcinoma).ti.
3 1 or 2
4 rt.fs.
5 radiotherapy dosage/
6 dose response relationship, radiation/
7 Dose Fractionation/
8 radiotherapy/
9 radiotherapy adjuvant/
10 exp radiotherapy, computer assisted/
11 or/4-10
12 (letter or news).pt.
13 (systematic$ adj3 (review$ or overview)).mp.
14 meta-analysis/ or meta-analysis.pt.
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15 13 or 14
16 3 and 11 and 15
17 16 not 12
18 randomized controlled trials/ or randomized controlled trial.pt.
19 randomization/ or double blind method/ or single blind method/
20 18 or 19
21 3 and 11 and 20
22 21 not 12
23 22 not 17
24 (breast cancer or breast neoplasm$ or breast adenocarcinoma).ti,ab.
25 (radiotherapy or radiation therapy).ti,ab.
26 (dose or dosage or fraction$).mp.
27 24 and 25 and 26
28 20 and 27
29 28 not 23
30 23 or 29
31 17 or 30
Appendix 2. Search strategy - EMBASE (Ovid) 1980 to 4 August 2009
1 breast cancer/ or breast adenocarcinoma/ or breast carcinoma/
2 (breast cancer or breast adenocarcinoma).ti.
3 1 or 2
4 Randomized Controlled Trial/
5 RANDOMIZATION/
6 Double Blind Procedure/
7 Single Blind Procedure/
8 or/4-7
9 3 and 8
10 radiotherapy/
11 radiation response/
12 radiation dose fractionation/
13 radiation dose/
14 radiation depth dose/
15 computer assisted radiotherapy/
16 rt.fs.
17 or/10-16
18 17 and 9
19 (breast cancer or breast neoplasm$ or breast adenocarcinoma).tw.
20 (radiotherapy or radiation).tw.
21 (dose or doses or dosage or fraction$).tw.
22 and/19-21
23 9 and 22
24 18 or 23
25 letter/
26 24 not 25
27 meta-analysis/
28 (meta-analy$ or metaanaly$).mp.
29 (systematic$ adj3 (review$ or overview)).mp.
30 or/27-29
31 22 and 30
32 3 and 17 and 30
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33 31 or 32
Appendix 3. Search strategy - WHO ICTRP Search Portal
Host: http://apps.who.int/trialsearch/
10 June 2010
Advanced search (with Recruitment set at ALL):
Search 1.
Condition field: breast cancer
Intervention field: fraction size AND radiation
Search 2.
Condition field: adenocarcinoma AND breast
Intervention field: radiation
Search 3.
Condition field: adenocarcinoma AND breast
Intervention field: irradiation
Search 4.
Condition: breast cancer
Intervention field: irradiation
Search 5.
Condition: breast cancer
Intervention: hypofractionated radiation
WH A T ’ S N E W
Last assessed as up-to-date: 22 June 2009.
Date Event Description
18 September 2009 New citation required and conclusions have changed Two new studies included, adding 4451 participants.
Conclusions changed and new outcomes presented
23 June 2009 New search has been performed Performed search for new studies on the 23rd June
2009.
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 3, 2008
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Date Event Description
11 April 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
The protocol was co-authored by Melissa James, Margot Lehman, Brigid Hickey, Phil Hider and Mark Jeffery.
Melissa James was involved in conceiving and designing the review, screening search results, organising paper retrieval, screening papers
against inclusion criteria, appraising quality of papers, writing to authors, screening data on unpublished studies, providing a clinical
perspective and writing the review. Melissa James provided clinical perspective, editing and checked the data for the update.
Brigid Hickey was involved in conceiving and designing the review, screening papers against the inclusion criteria, appraising the quality
of papers, extracting data, analysing data, providing a clinical perspective, writing the review, providing general advice and securing
funding for the initial review and the update. Brigid Hickey was involved in screening papers against inclusion criteria, appraising the
quality of papers, extracting data, analysing data, providing a clinical perspective, writing the review and providing general advice for
the update.
Margot Lehman was involved in screening papers against the inclusion criteria, appraising the quality of papers, securing funding,
extracting data, providing a clinical perspective and providing advice regarding the review, and securing funding for the initial review
and the update. Margot Lehman was involved in screening papers against inclusion criteria, appraising quality of papers, securing
funding, extracting data, providing a clinical perspective and providing advice regarding the review for the update.
Phil Hider was involved in designing the review, doing the search, providing methodological perspective, writing the review, and
providing general advice regarding the review.
Mark Jeffery was involved in designing the review, co-ordinating the review, screening search results, organising paper retrieval, screening
papers against the inclusion criteria, appraising quality of papers, writing to authors, obtaining data on unpublished studies, providing
clinical perspective and writing the review. Mark Jeffery provided clinical perspective and editing for the update.
Daniel Francis was involved in co-ordinating the review, doing the search, screening search results, organising paper retrieval, screening
against the inclusion criteria, writing to authors, providing a methodological perspective, writing the review and providing general
advice.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
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Internal sources
• Princess Alexandra Hospital Cancer Collaborative Group, Australia.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Women with T3 tumours (that is tumour size greater than 5 cm) were eligible for the START A 2008 and START B 2008 studies.
They comprised 1.6% (22/1410) of the women studied in Owen 2006. T stage was not reported in START A 2008 and START B
2008, but 0.15% (702/4451) women had tumours larger than 3 cm. T3 tumours (larger than 5 cm) account for 0.9% (724/7095) of
the total number of women studied.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Breast Neoplasms [∗radiotherapy; surgery]; Combined Modality Therapy [methods]; Dose Fractionation; Mastectomy, Segmental;
Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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